Climb Bio Total Current Assets 2021-2024 | CLYM

Climb Bio total current assets from 2021 to 2024. Total current assets can be defined as the sum of all assets that are classified as current because they will provide a benefit within one year.

Climb Bio Total Current Assets 2021-2024 | CLYM

Climb Bio total current assets from 2021 to 2024. Total current assets can be defined as the sum of all assets that are classified as current because they will provide a benefit within one year.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$174.4B
Vertex Pharmaceuticals (VRTX)$125.1B
Regeneron Pharmaceuticals (REGN)$111.8B
Bristol Myers Squibb (BMY)$106.8B
Gilead Sciences (GILD)$105.9B
CSL (CSLLY)$97.5B
GSK (GSK)$81.1B
Alnylam Pharmaceuticals (ALNY)$36.4B
Argenex SE (ARGX)$32.5B
BioNTech SE (BNTX)$28.6B
Biogen (BIIB)$27.9B
Illumina (ILMN)$23.7B
Moderna (MRNA)$22.2B
BeiGene (BGNE)$22.1B
Genmab (GMAB)$15.7B
BioMarin Pharmaceutical (BMRN)$13.3B
Exact Sciences (EXAS)$13.1B
Insmed (INSM)$12.9B
Vaxcyte (PCVX)$12.6B
Incyte (INCY)$12.6B
Sarepta Therapeutics (SRPT)$11.9B
Bio-Techne Corp (TECH)$11.7B
QIAGEN (QGEN)$10.1B
Bio-Rad Laboratories (BIO.B)$9.3B
Legend Biotech (LEGN)$9.1B
Roivant Sciences (ROIV)$8.8B
Revolution Medicines (RVMD)$8.2B
Repligen (RGEN)$8B
Intra-Cellular Therapies (ITCI)$7.8B
Ascendis Pharma (ASND)$7.8B